Limited, early-stage human data exist for this category
Novo Nordisk came to an agreement with the company to offer various doses of the GLP-1 medication for DTC customers
Our patients often ask if this is a quick fix
Treatment was well tolerated, but infections were common
During the visit, the provider may review medical history, current medications, wellness goals, previous treatments, possible contraindications, and whether peptide therapy fits the patients overall care plan
(CSE: SURE) (OTCQB: SURNF), (Profile) through its subsidiary GlucaPharm Inc., is advancing a differentiated next-generation GLP-1 platform centered on GEP-44, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in one of the fastest-growing pharmaceutical markets in history